Recently, Liu et al. reported that the inhibition of KIF18B or the administration of T09, a radiosensitizer targeting KIF18B, significantly enhances the radiosensitivity of sarcoma cells, delays tumor growth in both subcutaneous and orthotopic xenograft models, and prolongs the survival of murine subjects (Liu W. et al., 2020). Here, KIF18B is linked to sarcoma.